Systemic lupus erythematosus: Prediction by MRI of the subsequent development of brain lesions

Academic Radiology

Volumn 21, Issue 5, 2014, Pages 617-623

  Futatsuya, Koichiro ^a   Kakeda, Shingo ^a   Kaichi, Yoko ^b   Moriya, Junji ^a   Ohnari, Norihiro ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a   Korogi, Yukunori ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Antiphospholipid syndrome; Brain; MRI; Neuropsychiatric systemic lupus erythematosus; Prediction; Systemic lupus erythematosus

Indexed keywords

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN DAMAGE; BRAIN HEMORRHAGE; BRAIN STEM INFARCTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROEMBOLISM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; BRAIN; BRAIN VASCULITIS; DISEASE COURSE; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADULT; AGED; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84897522044     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2014.02.002     Document Type: Article

References (33)

1. Johnson R.T., Richardson E.P. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968, 47(4):337-369.
2. O'Connor J.F., Musher D.M. Central nervous system involvement in systemic lupus erythematosus. A study of 150 cases. Arch Neurol 1966, 14(2):157-164.
3. Bertsias G.K., Ioannidis J.P., Aringer M., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69(12):2074-2082.
4. Unterman A., Nolte J.E., Boaz M., et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011, 41(1):1-11.
5. Hanly J.G., Urowitz M.B., Su L., et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010, 69(3):529-535.
6. Hanly J.G., Su L., Farewell V., et al. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009, 36(7):1449-1459.
7. Sibbitt W.L., Brooks W.M., Kornfeld M., et al. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 2010, 40(1):32-52.
8. Kim J.H., Choi C.G., Choi S.J., et al. Primary antiphospholipid antibody syndrome: neuroradiologic findings in 11 patients. Korean J Radiol 2000, 1(1):5-10.
9. Vadacca M., Buzzulini F., Rigon A., et al. [Neuropsychiatric lupus erythematosus]. Reumatismo 2006, 58(3):177-186.
10. Govoni M., Bombardieri S., Bortoluzzi A., et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012, 51(1):157-168.
11. Kaichi Y., Kakeda S., Moriya J., et al. Brain MR findings in patients with systemic lupus erythematosus with and without antiphospholipid antibody syndrome. AJNR Am JNeuroradiol 2013.
12. Harris E.N., Pierangeli S.S. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name?. Semin Thromb Hemost 2008, 34(3):219-226.
13. Erkan D., Harrison M.J., Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007, 56(7):2382-2391.
14. Bernatsky S., Clarke A., Gladman D.D., et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 2006, 15(12):835-839.
15. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
16. Bombardier C., Gladman D.D., Urowitz M.B., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35(6):630-640.
17. Symmons D.P., Coppock J.S., Bacon P.A., et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988, 69(259):927-937.
18. Stoll T., Stucki G., Malik J., et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996, 55(10):756-760.
19. Lodder J., Hupperts R., Boreas A., et al. The size of territorial brain infarction on CT relates to thedegree of internal carotid artery obstruction. J Neurol 1996, 243(4):345-349.
20. Bang O.Y., Ovbiagele B., Liebeskind D.S., et al. Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke. J Neurol 2009, 256(4):591-599.
21. Kimura K., Minematsu K., Koga M., et al. Microembolic signals and diffusion-weighted MR imaging abnormalities in acute ischemic stroke. AJNR Am J Neuroradiol 2001, 22(6):1037-1042.
22. Bogousslavsky J., Regli F. Unilateral watershed cerebral infarcts. Neurology 1986, 36(3):373-377.
23. Damasio H. A computed tomographic guide to the identification of cerebral vascular territories. Arch Neurol 1983, 40(3):138-142.
24. Fisher C.M. Lacunar strokes and infarcts: a review. Neurology 1982, 32(8):871-876.
25. Fazekas F., Kleinert R., Offenbacher H., et al. The morphologic correlate of incidental punctate whitematter hyperintensities on MR images. AJNR Am J Neuroradiol 1991, 12(5):915-921.
26. Wuerfel J., Haertle M., Waiczies H., et al. Perivascular spaces-MRI marker of inflammatory activity in the brain?. Brain 2008, 131(Pt 9):2332-2340.
27. Chao C.P., Kotsenas A.L., Broderick D.F. Cerebral amyloid angiopathy: CT and MR imaging findings. Radiographics 2006, 26(5):1517-1531.
28. Sabet A., Sibbitt W.L., Stidley C.A., et al. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998, 29(11):2254-2260.
29. Atsumi T., Khamashta M.A., Haworth R.S., et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998, 41(5):800-807.
30. Duvernoy H.M., Delon S., Vannson J.L. Cortical blood vessels of the human brain. Brain Res Bull 1981, 7(5):519-579.
31. Hughes G.R., Khamashta M.A. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003, 62(12):1127.
32. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J., et al. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012, 71(2):242-244.
33. Erkan D., Yazici Y., Peterson M.G., et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41(8):924-929.